Kennedy Ferruggia, Associate Editor

Jennifer Griffin, PharmD, MS, discusses how pharmacists' accessibility and trust position them to fight vaccine misinformation and help close a coming gap in health care access as physician shortages loom.

This study strengthens the evidence base supporting current guidelines and may help reverse the recent decline in pediatric antiviral use.

Jerry P. Abraham, MD, MPH, CMQ, discusses the persistent risks of COVID-19 and how a newly approved postexposure prophylaxis option is reshaping pharmacists' role in prevention.

Hannaford's Sara Lane, PharmD, shares how standardized workflows and a growing technician immunizer program have driven measurable gains in vaccination rates.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

Jerry P. Abraham, MD, MPH, CMQ, discusses why COVID-19 prevention strategies, including ensitrelvir for postexposure prophylaxis, remain essential for protecting vulnerable patients amid persistent summer transmission.

Jerry P. Abraham, MD, MPH, CMQ, discusses how ensitrelvir's new post-exposure prophylaxis indication gives pharmacists a critical 72-hour window to help prevent COVID-19 in high-risk patients.

Morning appointments don't appear to offer any immunologic edge over afternoon ones, new data from more than 15 million patients suggest.

FDA clears ensitrelvir oral postexposure pill to prevent symptomatic COVID-19 after close contact, cutting infections in household trial with comparable safety.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

A yearlong trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.

GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.

Australian trial shows bivalent mRNA COVID-19 booster lifts antibodies more than protein vaccine, yet both cut infection similarly over 12 months.

Obesity must be treated as the lifelong, chronic condition it is, and pharmacists are essential to making that vision a reality.

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

Beckley Retreats CEO Neil Markey discusses how the recent executive order on psychedelic therapies for veterans could reshape access to ibogaine and other investigational treatments.

This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.

A study finds low-income and minority families are likely among those experiencing consequences from reduced measles, mumps, rubella, and varicella (MMRV) vaccine uptake amid the worst surge in US measles cases in decades.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

The authors said these data support the safety of current coadministration practice.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.